Benefits of Pharmacogenomics in Drug Development—Earlier Launch of Drugs and Less Adverse Events

ISSN： 0148-5598

Source： Journal of Medical Systems, Vol.34, Iss.4, 2010-08, pp. : 701-707

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adverse Patient Events and Knowledge Development Needs

By Redman Richard W.

Scholarly Inquiry for Nursing Practice, Vol. 20, Iss. 3, 2006-0 ,pp. : 187-189

Springer Publishing Company

Access to resources Recommend Favorite

Case Study: Reducing Adverse Drug Events Through Better Reporting and Analysis

Joint Commission Perspectives on Patient Safety, Vol. 4, Iss. 2, 2004-02 ,pp. : 9-10

Joint Commission Resources

Access to resources Recommend Favorite

Cognitive Aspects of Adverse Events

By Redman Richard W.

Scholarly Inquiry for Nursing Practice, Vol. 21, Iss. 1, 2007-03 ,pp. : 10-12

Springer Publishing Company

Access to resources Recommend Favorite

Medication Station: Reducing Anticoagulation-Related Adverse Drug Events: Closely monitoring and managing risks for patients on warfarin

Joint Commission Perspectives on Patient Safety, Vol. 6, Iss. 7, 2006-07 ,pp. : 3-4

Joint Commission Resources

Access to resources Recommend Favorite

Overview of Adverse Drug Reactions

Allergy and Asthma Proceedings, Vol. 15, Iss. 5, 1994-09 ,pp. : 243-244

OceanSide Publications, Inc

Access to resources Recommend Favorite